Lanthanides and their complexes for the treatment of bone density disorders

Lanthanides are of interest in the treatment of bone density disorders because they are found to accumulate preferentially in bone (in vivo), have a stimulatory effect on bone formation, and exhibit an inhibitory effect on bone degradation (in vitro), altering the homeostasis of the bone cycle. In a...

Full description

Bibliographic Details
Main Author: Mawani, Yasmin Jenny
Language:English
Published: University of British Columbia 2012
Online Access:http://hdl.handle.net/2429/43054
id ndltd-UBC-oai-circle.library.ubc.ca-2429-43054
record_format oai_dc
spelling ndltd-UBC-oai-circle.library.ubc.ca-2429-430542018-01-05T17:26:02Z Lanthanides and their complexes for the treatment of bone density disorders Mawani, Yasmin Jenny Lanthanides are of interest in the treatment of bone density disorders because they are found to accumulate preferentially in bone (in vivo), have a stimulatory effect on bone formation, and exhibit an inhibitory effect on bone degradation (in vitro), altering the homeostasis of the bone cycle. In an effort to develop an orally active lanthanide drug, a series of 3-hydroxy-4- pyridinone ligands were synthesized and eight of these ligands (H1 = 3-hydroxy-2-methyl-1- (2-hydroxyethyl)-4-pyridinone, H2 = 3-hydroxy-2-methyl-1-(3-hydroxypropyl)-4-pyridinone, H3 = 3-hydroxy-2-methyl-1-(4-hydroxybutyl)-4-pyridinone, H4 = 3-hydroxy-2- methyl-1-(2-hydroxypropyl)-4-pyridinone, H5 = 3-hydroxy-2-methyl-1-(1-hydroxy-3- methylbutan-2-yl)-4-pyridinone, H6 = 3-hydroxy-2-methyl-1-(1-hydroxybutan-2-yl)-4- pyridinone, H8 = 1-carboxymethyl-3-hydroxy-2-methyl-4-pyridinone, H9 = 1-carboxyethyl- 3-hydroxy-2-methyl-4-pyridinone) were coordinated to ³⁺(Ln = La, Eu, Gd, Lu) forming stable tris-ligand complexes (LnL­­₃, L = 1-, 2-, 3-, 4-, 5-, 6-, 8- and 9-). The dissociation (pKan) and metal ligand stability constants (log βn) of the 3-hydroxy-4-pyridinones with La³⁺ and Gd³⁺ were determined by potentiometric titrations, which demonstrated that the 3-hydroxy-4- pyridinones form stable tris-ligand complexes with the lanthanide ions. One phosphinate- EDTA derivative (H₅XT = bis[[bis(carboxymethyl)amino]methyl]phosphinate) was also synthesized and coordinated to Ln³⁺ (Ln = La, Eu, Lu), forming the potassium salt of [Ln(XT)]²-. Lastly, the naturally occurring curcuminoids found in turmeric were separated into the three naturally occurring components (HCurc = (1E,6E)-1-(4-hydroxy-3- methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione, HDMC = (1E,6E)-1,7- bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione, HBDMC = (1E,6E)-1,7-bis(4- hydroxy-phenyl)hepta-1,6-diene-3,5-dione); HCurc was then coordinated to Ln³⁺ (Ln = Eu, Gd, Yb, Lu), forming Ln(Curc)­­₃ complexes. The free ligands and metal complexes were studied for their in vitro efficacy. Cytotoxicity assays were carried out in MG-63 cells; with the exception of the curcuminoids, all the ligands and metal complexes tested were observed to be non-toxic to this cell line. Further studies to investigate the toxicity, cellular uptake and iii apparent permeability (Papp) of the lanthanide ions were conducted in Caco-2 cells and it was observed that [La(XT)]²- had the greatest cell uptake. Investigation into the binding affinities of free lanthanide ions (Ln = La, Gd and Lu), metal complexes and free 3-hydroxy-4-pyridinones with the bone mineral (HAP) indicate a strong binding affinity of the lanthanide ions for HAP, as well as a moderate to strong interaction of the free ligand with the bone mineral depending on the functional group. Science, Faculty of Chemistry, Department of Graduate 2012-08-24T23:21:22Z 2013-10-18T00:00:00Z 2012 2012-11 Text Thesis/Dissertation http://hdl.handle.net/2429/43054 eng Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ University of British Columbia
collection NDLTD
language English
sources NDLTD
description Lanthanides are of interest in the treatment of bone density disorders because they are found to accumulate preferentially in bone (in vivo), have a stimulatory effect on bone formation, and exhibit an inhibitory effect on bone degradation (in vitro), altering the homeostasis of the bone cycle. In an effort to develop an orally active lanthanide drug, a series of 3-hydroxy-4- pyridinone ligands were synthesized and eight of these ligands (H1 = 3-hydroxy-2-methyl-1- (2-hydroxyethyl)-4-pyridinone, H2 = 3-hydroxy-2-methyl-1-(3-hydroxypropyl)-4-pyridinone, H3 = 3-hydroxy-2-methyl-1-(4-hydroxybutyl)-4-pyridinone, H4 = 3-hydroxy-2- methyl-1-(2-hydroxypropyl)-4-pyridinone, H5 = 3-hydroxy-2-methyl-1-(1-hydroxy-3- methylbutan-2-yl)-4-pyridinone, H6 = 3-hydroxy-2-methyl-1-(1-hydroxybutan-2-yl)-4- pyridinone, H8 = 1-carboxymethyl-3-hydroxy-2-methyl-4-pyridinone, H9 = 1-carboxyethyl- 3-hydroxy-2-methyl-4-pyridinone) were coordinated to ³⁺(Ln = La, Eu, Gd, Lu) forming stable tris-ligand complexes (LnL­­₃, L = 1-, 2-, 3-, 4-, 5-, 6-, 8- and 9-). The dissociation (pKan) and metal ligand stability constants (log βn) of the 3-hydroxy-4-pyridinones with La³⁺ and Gd³⁺ were determined by potentiometric titrations, which demonstrated that the 3-hydroxy-4- pyridinones form stable tris-ligand complexes with the lanthanide ions. One phosphinate- EDTA derivative (H₅XT = bis[[bis(carboxymethyl)amino]methyl]phosphinate) was also synthesized and coordinated to Ln³⁺ (Ln = La, Eu, Lu), forming the potassium salt of [Ln(XT)]²-. Lastly, the naturally occurring curcuminoids found in turmeric were separated into the three naturally occurring components (HCurc = (1E,6E)-1-(4-hydroxy-3- methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione, HDMC = (1E,6E)-1,7- bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione, HBDMC = (1E,6E)-1,7-bis(4- hydroxy-phenyl)hepta-1,6-diene-3,5-dione); HCurc was then coordinated to Ln³⁺ (Ln = Eu, Gd, Yb, Lu), forming Ln(Curc)­­₃ complexes. The free ligands and metal complexes were studied for their in vitro efficacy. Cytotoxicity assays were carried out in MG-63 cells; with the exception of the curcuminoids, all the ligands and metal complexes tested were observed to be non-toxic to this cell line. Further studies to investigate the toxicity, cellular uptake and iii apparent permeability (Papp) of the lanthanide ions were conducted in Caco-2 cells and it was observed that [La(XT)]²- had the greatest cell uptake. Investigation into the binding affinities of free lanthanide ions (Ln = La, Gd and Lu), metal complexes and free 3-hydroxy-4-pyridinones with the bone mineral (HAP) indicate a strong binding affinity of the lanthanide ions for HAP, as well as a moderate to strong interaction of the free ligand with the bone mineral depending on the functional group. === Science, Faculty of === Chemistry, Department of === Graduate
author Mawani, Yasmin Jenny
spellingShingle Mawani, Yasmin Jenny
Lanthanides and their complexes for the treatment of bone density disorders
author_facet Mawani, Yasmin Jenny
author_sort Mawani, Yasmin Jenny
title Lanthanides and their complexes for the treatment of bone density disorders
title_short Lanthanides and their complexes for the treatment of bone density disorders
title_full Lanthanides and their complexes for the treatment of bone density disorders
title_fullStr Lanthanides and their complexes for the treatment of bone density disorders
title_full_unstemmed Lanthanides and their complexes for the treatment of bone density disorders
title_sort lanthanides and their complexes for the treatment of bone density disorders
publisher University of British Columbia
publishDate 2012
url http://hdl.handle.net/2429/43054
work_keys_str_mv AT mawaniyasminjenny lanthanidesandtheircomplexesforthetreatmentofbonedensitydisorders
_version_ 1718583459217145856